Immunogenicity and Safety of PEDIACEL, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to Infanrix-IPV+Hib When Both Vaccines Are Co-Administered With Prevenar to Infants and Toddlers at 2, 3, 4 and 12-18 Months of Age.

Trial Profile

Immunogenicity and Safety of PEDIACEL, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to Infanrix-IPV+Hib When Both Vaccines Are Co-Administered With Prevenar to Infants and Toddlers at 2, 3, 4 and 12-18 Months of Age.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2016

At a glance

  • Drugs Hib-DTaP-poliovirus vaccine; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Diphtheria; Haemophilus infections; Pertussis; Pneumococcal infections; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 26 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Apr 2008 The expected completion date for this trial is now 1 Jul 2009, as reported by clinicaltrials.gov.
    • 22 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top